Neuphoria Therapeutics Inc

Research Neuphoria Therapeutics Inc (NEUP) on Bullrun: valuation model: 198.0% undervalued, market cap USD 23.66M, P/E 3.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerNEUP
ExchangeNASDAQ
CountryUnited States
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
Valuation signal198.0% undervalued
Market capUSD 23.66M
P/E3.5
Financial periodFY2025
RevenueUSD 15.65M
Net income-USD 400.00K

Valuation Snapshot

Bullrun's latest valuation model marks Neuphoria Therapeutics Inc as 198.0% undervalued; latest market cap is USD 23.66M; P/E is 3.5.

About Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder.

Frequently asked questions

Is Neuphoria Therapeutics Inc overvalued or undervalued?

Bullrun's valuation model currently marks Neuphoria Therapeutics Inc as 198.0% undervalued.

What is Neuphoria Therapeutics Inc's market cap?

Neuphoria Therapeutics Inc's market capitalization is USD 23.66M.

What is Neuphoria Therapeutics Inc's P/E ratio?

Neuphoria Therapeutics Inc's price-to-earnings (P/E) ratio is 3.5.